Monday, May 03, 2021 10:22:44 PM
$ BPSR the Prequel to the Podcast. (Google EXOSOME THERAPY)[/img]
The long-term effects of COVID-19 infection can’t be comprehensively predicted. We don’t even understand why symptoms last only hours or days in some infected people, if they appear at all, yet linger for weeks and months for those dubbed “COVID long haulers.” Developing innovative biologics to treat COVID long haulers is the current mission of Miami-based Organicell Regenerative Medicine, though the company’s challenging therapy development journey began long before the idea curried much favor.
https://www.bioprocessonline.com/doc/beating-stem-cell-sourcing-exosome-production-challenges-0001
The long-term effects of COVID-19 infection can’t be comprehensively predicted. We don’t even understand why symptoms last only hours or days in some infected people, if they appear at all, yet linger for weeks and months for those dubbed “COVID long haulers.” Developing innovative biologics to treat COVID long haulers is the current mission of Miami-based Organicell Regenerative Medicine, though the company’s challenging therapy development journey began long before the idea curried much favor.
https://www.bioprocessonline.com/doc/beating-stem-cell-sourcing-exosome-production-challenges-0001
Recent ZEOX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:16:04 AM
- Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX (OTCQB:ZEOX) • ACCESS Newswire • 04/09/2026 11:00:00 AM
- ZEO ScientifiX (OTCQB: ZEOX) Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage • ACCESS Newswire • 04/07/2026 05:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 11:50:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 08:05:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 08:17:09 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/06/2026 11:54:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/29/2026 09:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 11:01:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 10:17:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 01:00:48 PM
- Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States • ACCESS Newswire • 01/07/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 11:02:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 09:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2025 12:30:32 PM
- ZEO ScientifiX(TM) Positioned for New Growth as Florida Opens Stem Cell Market • ACCESS Newswire • 10/23/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/15/2025 08:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2025 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2025 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2025 12:45:20 PM
